Privium Fund Management B.V. Takes $909,000 Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Privium Fund Management B.V. acquired a new stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 138,115 shares of the company’s stock, valued at approximately $909,000. Privium Fund Management B.V. owned approximately 0.42% of Lexeo Therapeutics at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Geode Capital Management LLC grew its holdings in Lexeo Therapeutics by 86.5% during the third quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock worth $5,003,000 after purchasing an additional 256,635 shares during the period. State Street Corp grew its holdings in Lexeo Therapeutics by 29.4% during the third quarter. State Street Corp now owns 253,946 shares of the company’s stock worth $2,296,000 after purchasing an additional 57,674 shares during the period. Frazier Life Sciences Management L.P. bought a new position in Lexeo Therapeutics during the third quarter worth about $11,307,000. Barclays PLC grew its holdings in Lexeo Therapeutics by 162.2% during the third quarter. Barclays PLC now owns 50,210 shares of the company’s stock worth $454,000 after purchasing an additional 31,057 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in Lexeo Therapeutics by 18.9% during the third quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock worth $33,997,000 after purchasing an additional 599,203 shares during the period. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Trading Down 4.8 %

Shares of LXEO stock opened at $2.96 on Wednesday. The firm has a 50 day moving average price of $4.42 and a two-hundred day moving average price of $6.94. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $97.88 million, a PE ratio of -0.94 and a beta of 3.85. Lexeo Therapeutics, Inc. has a 12-month low of $2.32 and a 12-month high of $19.50.

Analysts Set New Price Targets

Separately, Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, January 21st. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $23.80.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.